BioCentury | Jun 15, 2018
Clinical News

Vical discontinuing HSV-2 program after Phase II miss

...that were both clinically and virologically confirmed during a minimum of nine months of surveillance. Vical...
...trial to treat invasive aspergillosis, which could support a limited use indication approval from FDA. Vical...
...Product (QIDP), Orphan Drug and Fast Track designations in the U.S. to treat invasive aspergillosis. Vical...
BioCentury | Jun 11, 2018
Clinical News

Vical discontinuing HSV-2 program after Phase II miss

...infection. VCL-HB01 missed the primary endpoint of reducing the annualized lesion recurrence rate vs. placebo. Vical...
...trial to treat invasive aspergillosis, which could support a limited use indication approval from FDA. Vical...
...Product (QIDP), Orphan Drug and Fast Track designations in the U.S. to treat invasive aspergillosis. Vical...
BioCentury | Jan 26, 2018
Clinical News

Astellas/Vical CMV vaccine ASP0113 fails stem cell transplant trial

...Astellas Pharma Inc. (Tokyo:4503) and partner Vical Inc. (NASDAQ:VICL) said cytomegalovirus (CMV) vaccine ASP0113 missed the primary...
...transplant patients receiving an organ from a CMV-seropositive donor (see BioCentury, Sept. 26, 2016 ). Vical Inc....
...antiviral therapy for CMV end-organ disease Status: Phase III data Milestone: NA Jaime De Leon ASP0113 VCL-CB01 Astellas Pharma Inc. Vical Inc. Human...
BioCentury | Jan 22, 2018
Clinical News

Astellas/Vical CMV vaccine fails stem cell transplant trial

...Astellas Pharma Inc. (Tokyo:4503) and partner Vical Inc. (NASDAQ:VICL) said cytomegalovirus (CMV) vaccine ASP0113 missed the primary...
...secondary endpoints in the Phase III HELIOS trial in CMV-seropositive allogeneic stem cell transplant recipients. Vical...
...patients receiving an organ from a CMV-seropositive donor (see BioCentury Extra, Sept. 19, 2016) . Vical’s...
BioCentury | Jan 13, 2018
Finance

Choosy investors

...$37.5 NA $60.6 NA RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) 11/8/17 $22.5 $116.9 $109.3 -7% Vical Inc....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...CLL and small cell lymphocytic lymphoma (SLL); relapsed or refractory follicular lymphoma Submit NDA 1Q18 Vical Inc....
BioCentury | Dec 22, 2017
Product R&D

Dengvaxia’s warning

...A) Naval Medical Research Center tested formulations both with and without Vaxfectin adjuvant technology from Vical Inc....
BioCentury | Jun 2, 2017
Clinical News

Vical completes enrollment in Phase II of HSV-2 vaccine

...In April, Vical Inc. (NASDAQ:VICL) completed enrollment of 225 adults with symptomatic genital herpes simplex virus type...
...endpoints include safety, time to first recurrence and proportion of patients who are recurrence free. Vical...
...encoding the HSV-2 glycoprotein D and tegument protein VP11/12 (UL46) formulated with Vaxfectin lipid adjuvant. Vical Inc....
BioCentury | Feb 28, 2017
Clinical News

Merck CMV prophylaxis headed for U.S., EU submissions

...infection through week 24 in HSCT recipients in the Phase III SUPPRESS trial. ASP0113 from Vical Inc....
BioCentury | Oct 10, 2016
Clinical News

Herpes simplex virus type 2: Phase II started

...evaluate 1 mL intramuscular VCL-HB01 every 28 days for 4 doses in about 225 patients. Vical Inc....
Items per page:
1 - 10 of 514
BioCentury | Jun 15, 2018
Clinical News

Vical discontinuing HSV-2 program after Phase II miss

...that were both clinically and virologically confirmed during a minimum of nine months of surveillance. Vical...
...trial to treat invasive aspergillosis, which could support a limited use indication approval from FDA. Vical...
...Product (QIDP), Orphan Drug and Fast Track designations in the U.S. to treat invasive aspergillosis. Vical...
BioCentury | Jun 11, 2018
Clinical News

Vical discontinuing HSV-2 program after Phase II miss

...infection. VCL-HB01 missed the primary endpoint of reducing the annualized lesion recurrence rate vs. placebo. Vical...
...trial to treat invasive aspergillosis, which could support a limited use indication approval from FDA. Vical...
...Product (QIDP), Orphan Drug and Fast Track designations in the U.S. to treat invasive aspergillosis. Vical...
BioCentury | Jan 26, 2018
Clinical News

Astellas/Vical CMV vaccine ASP0113 fails stem cell transplant trial

...Astellas Pharma Inc. (Tokyo:4503) and partner Vical Inc. (NASDAQ:VICL) said cytomegalovirus (CMV) vaccine ASP0113 missed the primary...
...transplant patients receiving an organ from a CMV-seropositive donor (see BioCentury, Sept. 26, 2016 ). Vical Inc....
...antiviral therapy for CMV end-organ disease Status: Phase III data Milestone: NA Jaime De Leon ASP0113 VCL-CB01 Astellas Pharma Inc. Vical Inc. Human...
BioCentury | Jan 22, 2018
Clinical News

Astellas/Vical CMV vaccine fails stem cell transplant trial

...Astellas Pharma Inc. (Tokyo:4503) and partner Vical Inc. (NASDAQ:VICL) said cytomegalovirus (CMV) vaccine ASP0113 missed the primary...
...secondary endpoints in the Phase III HELIOS trial in CMV-seropositive allogeneic stem cell transplant recipients. Vical...
...patients receiving an organ from a CMV-seropositive donor (see BioCentury Extra, Sept. 19, 2016) . Vical’s...
BioCentury | Jan 13, 2018
Finance

Choosy investors

...$37.5 NA $60.6 NA RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) 11/8/17 $22.5 $116.9 $109.3 -7% Vical Inc....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...CLL and small cell lymphocytic lymphoma (SLL); relapsed or refractory follicular lymphoma Submit NDA 1Q18 Vical Inc....
BioCentury | Dec 22, 2017
Product R&D

Dengvaxia’s warning

...A) Naval Medical Research Center tested formulations both with and without Vaxfectin adjuvant technology from Vical Inc....
BioCentury | Jun 2, 2017
Clinical News

Vical completes enrollment in Phase II of HSV-2 vaccine

...In April, Vical Inc. (NASDAQ:VICL) completed enrollment of 225 adults with symptomatic genital herpes simplex virus type...
...endpoints include safety, time to first recurrence and proportion of patients who are recurrence free. Vical...
...encoding the HSV-2 glycoprotein D and tegument protein VP11/12 (UL46) formulated with Vaxfectin lipid adjuvant. Vical Inc....
BioCentury | Feb 28, 2017
Clinical News

Merck CMV prophylaxis headed for U.S., EU submissions

...infection through week 24 in HSCT recipients in the Phase III SUPPRESS trial. ASP0113 from Vical Inc....
BioCentury | Oct 10, 2016
Clinical News

Herpes simplex virus type 2: Phase II started

...evaluate 1 mL intramuscular VCL-HB01 every 28 days for 4 doses in about 225 patients. Vical Inc....
Items per page:
1 - 10 of 514